Top stories in endocrinology: Trial tests dapagliflozin as COVID-19 treatment, recommended diabetes agents in presence of coronavirus
A global phase 3 trial is underway to assess the potential of dapagliflozin as a treatment to reduce COVID-19 progression among adults with cardiovascular, metabolic or renal risk factors. It was the top story last week in endocrinology.
Another top story was about a review that concluded there is insufficient evidence to recommend DPP-IV inhibitor treatment for patients with type 2 diabetes and COVID-19.
Read these and more of last week’s top stories in endocrinology below:
Clinical trial investigates dapagliflozin for COVID-19 treatment
Recruitment for a global phase 3 trial is now underway to assess the potential of the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) as a treatment to reduce COVID-19 progression, complications and death among adults with cardiovascular, metabolic or renal risk factors. Read more.
'Insufficient evidence' to recommend DPP-IV inhibitor treatment in type 2 diabetes with COVID-19
Insulin — not DPP-IV inhibitors or GLP-1 receptor agonists — should be the agent of choice for the management of severely ill patients with diabetes and coronavirus infections; this position is supported by extensive historical experience and the increased adoption of continuous glucose monitoring, according to a literature review published in Endocrine Reviews. Read more.
Beyond COVID-19: The future of telehealth in endocrinology
As clinicians around the country rapidly transition from in-person to telehealth visits, many changes must be managed at once. Endocrinologists in particular are working to find new ways to support people with diabetes who rely on data-driven care and multiple in-person visits each year, and the shift has left many wondering what may come next now that certain telehealth regulations have been temporarily loosened. Read more.
‘We knew we needed to get creative’: Inside Mount Sinai’s effort to make glucose management safer during COVID-19
The risk for severe COVID-19 complications is significantly higher for people with diabetes, and glucose management may play a vital role in disease outcomes. At the same time, careful monitoring of inpatient glucose can prove unsafe for clinicians and nurses, who must repeatedly put themselves at risk to perform routine fingersticks for glucose monitoring. Read more.
Preoperative metformin reduces mortality, readmission risks for patients with type 2 diabetes
Patients with type 2 diabetes who were prescribed metformin prior to a major surgery had reduced risks for mortality and readmission in the 90 days following the procedure, according to a retrospective cohort study published in JAMA Surgery. Read more.